Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Wegovy and Zepbound belong to the same class of medications, known as GLP-1s, but they work in slightly different ways. In a recent head-to-head study, Zepbound was shown to be more effective than ...

If you want to continue GLP-1 therapy, you’ll likely need to switch to a brand-name GLP-1. Examples of these include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound).

The company pledged to soon make its highest marketed Zepbound strengths, the drug's 12.5 mg and 15 mg doses, available in single-dose vials for $499 a month through its LillyDirect self-pay ...

In interviews, patients said that they had specifically sought out Zepbound and didn’t want to switch. “I chose Zepbound with my doctor,” said Carl Houde, 49, of Saugus, Mass.

According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds, while those who took semaglutide, or ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

While Zepbound leads today, the next potential rally may be sparked by Orforglipron, Eli Lilly's small-molecule oral GLP-1. Phase 3 obesity data is expected in the third quarter, with a launch ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Doctors favored CPAP over Zepbound 53% to 26%, while patients favored Zepbound over CPAP 48% to 35%. Both doctors and patients supported treatment that combined CPAP and Zepbound, but doctors were ...

For the first time, a study in The New England Journal of Medicine is comparing the most popular drugs for weight loss, Zepbound and Wegovy. NBC News medical contributor Dr. Natalie Azar joins ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.